Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Johnson and Johnson
Mallinckrodt
Express Scripts
McKesson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Rituximab; hyaluronidase (human recombinant) - Biologic Drug Details

See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for rituximab; hyaluronidase (human recombinant)

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Emory UniversityPhase 2
Genentech, Inc.Phase 2
Fred Hutchinson Cancer Research CenterPhase 1

See all rituximab; hyaluronidase (human recombinant) clinical trials

Recent Litigation for rituximab; hyaluronidase (human recombinant)

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.2019-07-12
CELGENE CORPORATION v. APOTEX INC.2019-06-19
Genentech, Inc. v. Pfizer Inc.2019-04-05

See all rituximab; hyaluronidase (human recombinant) litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all rituximab; hyaluronidase (human recombinant) litigation

Patent Text Search: US Patents for rituximab; hyaluronidase (human recombinant)

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab; hyaluronidase (human recombinant)

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
138 Luxembourg   Start Trial PRODUCT NAME: RITUXIMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20140326
2475353/01 Switzerland   Start Trial PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
C00044 Luxembourg   Start Trial PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703
2017 00061 Denmark   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196/001-8 20170627
2015017 Lithuania   Start Trial PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Harvard Business School
Dow
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.